MedTrace Logo

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

Conditions

Interventions

DRUG

Daratumumab SC

Daratumumab will be administered subcutaneously.

DRUG

Lenalidomide

Lenalidomide will be self-administered orally.

DRUG

Pomalidomide

Pomalidomide will be self-administered orally.

DRUG

Talquetamab

Talquetamab will be administered subcutaneously.

DRUG

Carfilzomib

Carfilzomib will be administered as an IV infusion.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2025-03-31
Completion
2027-10-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05050097 on ClinicalTrials.gov